ZyVersa Therapeutics Net Profit Margin 2022-2024 | ZVSA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

ZyVersa Therapeutics net profit margin from 2022 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

ZyVersa Therapeutics net profit margin from 2022 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$152.1B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$120.1B
Gilead Sciences (GILD)	$115.4B
CSL (CSLLY)	$89B
Regeneron Pharmaceuticals (REGN)	$82.4B
GSK (GSK)	$70.7B
Argenex SE (ARGX)	$37.2B
Alnylam Pharmaceuticals (ALNY)	$32.6B
BioNTech SE (BNTX)	$28.4B
Biogen (BIIB)	$23.4B
Illumina (ILMN)	$22.9B
BeiGene (BGNE)	$20.9B
Moderna (MRNA)	$16.6B
Incyte (INCY)	$14.4B
Genmab (GMAB)	$14.2B
Insmed (INSM)	$13.4B
Sarepta Therapeutics (SRPT)	$12.7B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$12B
Vaxcyte (PCVX)	$11.8B
Exact Sciences (EXAS)	$11.5B
Exelixis (EXEL)	$10.4B
QIAGEN (QGEN)	$9.9B
Revolution Medicines (RVMD)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$9.3B
Intra-Cellular Therapies (ITCI)	$9.1B
Repligen (RGEN)	$8.4B
Ascendis Pharma (ASND)	$8.3B